Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial

Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first…

Continue Reading

News Source: medicalxpress.com